प्रगत एंझाईम तंत्रज्ञान शेअर किंमत

Q4FY26 आणि पूर्ण वर्षाची कामगिरी आणि दृष्टीकोन यावर प्रगत एन्झाईम टेक्नॉलॉजीज मॅनेजमेंट आणि विश्लेषकांसह कॉन्फरन्स कॉल. पूर्ण कमाईची ट्रान्सक्रिप्ट ऐका.

• ट्रेंडलाईन
• 1 महिन्यापूर्वी

Biotechnology company Advanced Enzyme Technologies announced Q4FY26 & FY26 results Financial Highlights: Revenue from Operations: Reached Rs 2,034 million in Q4FY26, registering a growth of 22% YoY from Rs 1,672 million in Q4FY25, and an 18% QoQ increase from Rs 1,719 million in Q3FY26. For FY26, revenue increased by 17% YoY to Rs 7,458 million compared to Rs 6,369 million in FY25. EBITDA: Stood at Rs 632 million in Q4FY26, representing an increase of 39% YoY from Rs 456 million in Q4FY25, and higher by 28% QoQ compared to Rs 494 million in Q3FY26. For FY26, EBITDA grew by 18% YoY to Rs 2,291 million from Rs 1,944 million in FY25. EBITDA Margin: Maintained at 31% in Q4FY26 (up from 27% in Q4FY25 and 29% in Q3FY26). For FY26, the margin remained stable at 31%. Profit Before Tax (PBT): Clocked at Rs 598 million in Q4FY26, an increase of 38% YoY against Rs 435 million in Q4FY25, and up 3% QoQ from Rs 583 million in Q3FY26. FY26 PBT stood at Rs 2,325 million, growing 24% YoY from Rs 1,874 million in FY25. Profit After Tax (PAT): Surged by 69% YoY to Rs 453 million in Q4FY26 from Rs 267 million in Q4FY25, and recorded a 5% QoQ growth from Rs 432 million in Q3FY26. For FY26, PAT increased by 30% YoY to Rs 1,736 million from Rs 1,340 million in FY25. Earnings Per Share (EPS): Stood at Rs 3.84 in Q4FY26 (up 62% YoY from Rs 2.37 in Q4FY25 and up 1% QoQ from Rs 3.80 in Q3FY26). For FY26, EPS increased by 29% YoY to Rs 15.08 compared to Rs 11.72 in FY25. Business & Segment Highlights: Segment-wise Performance: Human Nutrition: Reached Rs 4,674 million, a 15% YoY growth. Animal Nutrition: Demonstrated robust growth of 25% YoY to Rs 946 million. Bio-Processing: Grew by 16% YoY to Rs 1,176 million. Specialized Manufacturing: Contributed 9% to total revenue, growing by 23% YoY to Rs 662 million. Geographical Revenue: Domestic Sales: Accounted for 52% of total revenue in Q4FY26 at Rs 1,061 million (up 51% YoY and 32% QoQ). For FY26, domestic sales amounted to Rs 3,727 million, representing a 28% YoY increase. International Sales: Accounted for 48% of total revenue in Q4FY26 at Rs 973 million (up 1% YoY and 6% QoQ). For FY26, international sales contributed Rs 3,731 million, reflecting an 8% YoY growth. Operational & Strategic Updates: The company launched its own nutraceutical brand, 'Wellfa', targeting Indian consumers to expand its B2C presence in the Human Nutrition sector. Maintained its status as a zero-debt entity, having successfully completed four acquisitions over the past nine years financed entirely through internal accruals. In the Baking segment, the company submitted 15 dossiers to the European Food Safety Authority (EFSA) and has received positive opinions for 9 of them. Result PDF

• ट्रेंडलाईन
• 1 महिन्यापूर्वी

बायोटेक्नॉलॉजी कंपनी ॲडव्हान्स्ड एंजाइम टेक्नॉलॉजीजने Q3FY26 परिणामांची घोषणा केली आहे. एकत्रित आधारावर ऑपरेशन्सचा महसूल Q3FY26 मध्ये ₹1,719 दशलक्ष पर्यंत वाढला आहे. Q3FY25 मध्ये ₹1,691 दशलक्ष, 2% ची वाढ. Q3FY26 दरम्यान एकत्रित EBITDA Q3FY25 दरम्यान ₹ 553 दशलक्षच्या तुलनेत ₹ 494 दशलक्ष आहे, 11% ची घट. Q3FY26 दरम्यान टॅक्स पूर्वीचा नफा ₹583 दशलक्ष आहे. Q3FY25 मध्ये ₹530 दशलक्ष, 10% ची वाढ. करानंतर नफा 11% ने वाढला आणि Q3FY26 दरम्यान ₹ 432 दशलक्ष आहे, Q3FY25 दरम्यान ₹ 389 दशलक्षच्या तुलनेत. EBITDA मार्जिन 29% आहे, PBT मार्जिन 34% आहे आणि तिमाहीत PAT मार्जिन 25% आहे. Q3FY26 दरम्यान आर्थिक खर्च रु. 6 दशलक्ष होता, Q3FY25 मध्ये रु. 9 दशलक्ष होता. Q3FY26 साठी डेप्रीसिएशन आणि अमॉर्टायझेशन शुल्क Q3FY25 मध्ये ₹ 90 दशलक्षच्या तुलनेत ₹ 102 दशलक्ष होते. Q3FY26 दरम्यान प्रति शेअर कमाई Q3FY25 मध्ये ₹ 3.36 च्या तुलनेत ₹ 3.80 आहे. रिझल्ट PDF

• ट्रेंडलाईन
• 4 महिने 1 आठवड्यापूर्वी